May 17th 2024
Tarlatamab — now with the brand name Imdelltra — is the first approved bispecific antibody for a solid tumor.
FDA Grants Priority Review for Therapy for Life-threatening Hereditary Immune Disease
February 23rd 2023If approved, pozelimab would be the first treatment for CHAPLE disease, which causes damage to blood and lymph vessels along the upper digestive tract. The target action date for the FDA decision is Aug. 20, 2023.